Company / SG&A Expense
BioRestorative Therapies, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$5.9M
FY2025
5-year range
$5.9M / $25.6M
FY2021-FY2025
Trend
-48.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $11M to $6M over the past 2 years.
Based on SEC 10-K filings.
$6M in FY2025 with a 5-year CAGR of +5.0%.
Improved from $11M to $6M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -27.7%
- 5-Year CAGR
- +5.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +5.0%, indicating consistent growth.
- In FY2025, sg&a expense decreased 48.0% year-over-year.
- Peak sg&a expense was recorded in FY2021.
- Lowest sg&a expense in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -47.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.9M | -48.0% |
| FY2024 | $11.3M | +0.0% |
| FY2023 | $11.3M | -27.3% |
| FY2022 | $15.6M | -39.2% |
| FY2021 | $25.6M | +456.4% |
| FY2020 | $4.6M | +14.5% |
| FY2019 | $4.0M | +3.1% |
| FY2018 | $3.9M | +20.3% |
| FY2017 | $3.2M | -16.1% |
| FY2016 | $3.9M | +71.4% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026